Brief communication: immunogenicity of measles vaccine when co-administered with 10-valent pneumococcal conjugate vaccine

Zheng Quan Toh,Paul V Licciardi,Tran Ngoc Huu,Vo Thi Trang Dai,Lien Anh Ha Do,Doan Y Uyen,Beth Temple,E Kim Mulholland,Kathryn Bright,Nguyen Trong Toan

doi:10.1038/s41541-020-00225-z

Abstract

This brief communication describes the findings from a randomised controlled trial in Vietnam that co-administration of measles vaccine (MV) with 10-valent pneumococcal conjugate vaccine (PCV10, Synflorix®, GSK) does not affect the immunogenicity of MV. These findings are most relevant for low- and middle-income countries (LMICs) in Asia considering PCV introduction.

Highlights

Measles is one of the most highly contagious human pathogens, accounting for significant morbidity and mortality worldwide, with the highest burden in low- and lower-middle-income countries[1]
As a secondary analysis within a randomised, single-blind controlled trial of alternative pneumococcal conjugate vaccines (PCV) schedules in Vietnam[6], we investigated whether co-administration of PCV10 with measles vaccine (MV) at 9 months of age interferes with the immunogenicity of MV
Blood samples were collected at 10 months of age, from 144 participants who received both MV and PCV10 and from 133 participants who received MV alone at 9 months of age

Summary

Introduction

Measles is one of the most highly contagious human pathogens, accounting for significant morbidity and mortality worldwide, with the highest burden in low- and lower-middle-income countries[1]. One important consideration for countries planning to introduce PCV is whether it will interfere with the immunogenicity of other EPI vaccines. In Vietnam, measles vaccination is given as two-dose schedule under the EPI; MV (AIK-C strain, POLYVAC, Vietnam) at 9 months of age and measles–rubella (MR) combination vaccine at 18 months of age.

Results

Conclusion